Attached To Peptide Or Protein Of 2+ Amino Acid Units (e.g., Dipeptide, Folate, Fibrinogen, Transferrin, Sp. Enzymes); Derivative Thereof Patents (Class 424/1.69)
  • Patent number: 11389544
    Abstract: The present invention provides nanoparticle conjugates incorporating the self-assembling module diphenylalanine (FF) dipeptide into a bioactive moiety. The conjugate self-assembles to form distinct nanometric structures such as nanospheres. The present invention further provides nanoparticles formed by supramolecular co-assembly of the conjugates with a diphenylalanine (FF) dipeptide or analog thereof, to generate bioactive self-assembled nanostructures.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: July 19, 2022
    Assignees: RAMOT AT TEL-AVIV UNIVERSITY LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Talia Shekhter Zehavi, Ehud Gazit, Mor Herman-Oron, Genady Kostenich, Arie Orenstein
  • Patent number: 11352389
    Abstract: Novel nucleic acid sequences, vectors, modified cells, peptides and pharmaceutical compositions are provided that are useful in the treatment of human subjects having a ?NPM1 positive haematological malignancy. Corresponding methods and uses are also provided.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: June 7, 2022
    Assignee: Academisch Ziekenhuis Leiden (h.o.d.n. Leids Universitair Medisch Centrum)
    Inventors: Marieke Griffioen, J. H. Frederik Falkenburg
  • Patent number: 11311636
    Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to radiotracer compositions which comprises 18F-labelled c-Met binding peptides. The invention provides said compositions, as well as associated automated methods of preparation and cassettes.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: April 26, 2022
    Assignee: GE HEALTHCARE LIMITED
    Inventors: Torgrim Engell, Gareth Simon Getvoldsen, Andreas Richard Meijer, Imtiaz Ahmed Khan, Graeme McRobbie, Robert James Nairne
  • Patent number: 11298424
    Abstract: The present invention is directed to copolypeptide hydrogels (DCH) containing non-ionic hydrophilic residues (DCHEO), incorporation of thermoresponsive elements into DCHEO, to generate thermoresponsive DCH (DCHT), and hydrogels that include a combination of DCHEO and DCHT. The invention includes preparation, uses, compositions containing the hydrogels and methods of tuning the hydrogels. The hydrogels can be used to deliver an agent or cells to an organism.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: April 12, 2022
    Assignee: The Regents of the University of California
    Inventors: Timothy J. Deming, Michael V. Sofroniew, Shanshan Zhang
  • Patent number: 11279962
    Abstract: The invention relates to the field of polymer production, in particular to the production of chitin and chitosan from microalgae belonging to the phylum Haptophyta to the phylum Chlorophyta, or to the phylum Heterokontophyta, particularly from microalgae of the genus Isochrysis, Chlorella, Bracteacoccus, Chlorococcum, Scenedesmns, Desmodesmus, Haematococcus, Thalassiosira and Nannochloropsis, as well as to microalgal extracts thereof and their uses.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: March 22, 2022
    Assignee: Algaktiv, S.L.
    Inventors: Derek Georges Latil De Ros, María Teresa López Cerro, Eugenia Ruiz Canovas, Olga Durany Turk, Jordi Segura De Yebra, Jaume Mercadé Roca, Daniel Pérez Reyes, Xavier Álvarez Mico
  • Patent number: 11266603
    Abstract: Disclosed herein are novel synthetic polypeptides and uses thereof in the preparation of liposomes. According to embodiments of the present disclosure, the synthetic polypeptide comprises a membrane lytic motif, a masking motif, and a linker configured to link the membrane lytic motif and the masking motif. The linker is cleavable by a stimulus, such as, light, protease, or phosphatase. Once being coupled to a liposome, the exposure to the stimulus cleaves the linker that results in the separation of the masking motif from the membrane lytic motif, which in turn exerts membrane lytic activity on the liposome that leads to the collapse of the intact structure of the liposome, and releases the agent encapsulated in the liposome to the target site. Also disclosed herein are methods of diagnosing or treating a disease in a subject by use of the present liposomes.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: March 8, 2022
    Inventors: Hsien-Ming Lee, Hua-De Gao, Jia-Lin Hong, Chih-Yu Kuo, Cheng-Bang Jian
  • Patent number: 11260133
    Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: March 1, 2022
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara
  • Patent number: 11253456
    Abstract: An anti-inflammatory peptide comprises an anti-inflammatory fragment of a protein selected from SEQ ID NOs: 1 to 16, the anti-inflammatory fragment being 7 to 37 amino acids in length and having a charge of between ?9 and +3; wherein the c-terminal amino acid is not cysteine (C) or methionine (M), and the n-terminal amino acid is not cysteine (C), histidine (H), proline (P) or threonine (T). The anti-inflammatory fragment does not contain cysteine (C). The anti-inflammatory fragment is from a region of the proteins of SEQ ID NOs: 1 to 16, which region is characterised by being 17 to 109 amino acids in length and having a charge of between ?6 and +4, wherein the c-terminal amino acid of the region is not aspartic acid (D), phenylalanine (F), methionine (M) or tryptophan (W), and the n-terminal amino acid of the region is not aspartic acid (D), histidine (H), methionine (M), proline (P) or tryptophan (W). Examples of peptides are provided in SEQ ID NOs: 71 to 221.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: February 22, 2022
    Assignee: NURITAS LIMITED
    Inventors: Nora Khaldi, Cyril Lopez, Alessandro Adelfio
  • Patent number: 11246940
    Abstract: Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)-M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 15, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Roger Tsien, Todd Aguilera, Emilia Olson, Tao Jiang, Quyen Nguyen
  • Patent number: 11191854
    Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 7, 2021
    Assignee: Centre for Probe Development and Commercialization
    Inventors: Eric Steven Burak, Stuart James Mahoney, Ryan Wayne Simms, John Fitzmaurice Valliant, Alla Darwish
  • Patent number: 11185794
    Abstract: Described are a fraction collector and a method of fraction collection for a liquid chromatography system. The method includes diverting a liquid chromatography system flow from a waste channel to a collection tube at a start of a fraction collection window and collecting the system flow dispensed from the collection tube during the fraction collection window. At the end of the window, the system flow is diverted to the waste channel and a flow of a wash solvent is provided to the collection tube to dispense liquid remaining in the collection tube at the end of the window from the collection tube. The method can increase the amount of the collected fraction and can reduce or eliminate cross-contamination of a subsequently collected fraction. The method is useful for analytical scale applications where the collected fractions may have volumes defined by a limited number of drops dispensed from the collection tube.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: November 30, 2021
    Assignee: WATERS TECHNOLOGIES CORPORATION
    Inventors: Joshua A. Burnett, James Usowicz, Marc Lemelin, Lucas O. Tiziani, John Lamoureux, Aaron Lebeau
  • Patent number: 11160887
    Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds comprising a cyclic peptide wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention will also be useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: November 2, 2021
    Assignee: UNM Rainforest Innovations
    Inventors: Yubin Miao, Haixun Guo
  • Patent number: 11141526
    Abstract: Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: October 12, 2021
    Assignee: BetaGlue Technologies S.p.A
    Inventors: Antonino Amato, Giovanni Paganelli
  • Patent number: 11136251
    Abstract: The present disclosure provides compositions, methods, and devices for sensing, detecting, and/or selectively capturing phosphate from water. An exemplary method includes: contacting a ligand or a rare earth metal complex of a ligand as described herein with an aqueous phosphate-containing medium at a pH of 5 to 12 under conditions sufficient to bind phosphate (e.g., reversibly bind phosphate). In certain embodiments, the method further includes releasing the bound phosphate by contacting the bound phosphate complex with an aqueous medium at a pH of 0 to 4 under conditions sufficient to release the bound phosphate.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 5, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Valerie Christine Pierre, Sylvie Lilliane Pailloux, Sheng-Yin Huang, Mandapati V. Ramakrishnam Raju
  • Patent number: 11129912
    Abstract: The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177Lu-PSMA I&T.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: September 28, 2021
    Assignee: POINT Biopharma Inc.
    Inventor: Joe McCann
  • Patent number: 11099198
    Abstract: Methods are described for determining the amount of insulin in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying insulin in a biological sample utilizing purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: August 24, 2021
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Zhaohui Chen, Nigel Clarke
  • Patent number: 11094424
    Abstract: The present invention provides a system for evaporating a radioactive fluid, a method for the synthesis of a radiolabelled compound including this system, and a cassette for the synthesis of a radiolabelled compound comprising this system. The present invention provides advantages over known methods for evaporation of a radioactive fluid as it reduces drastically the amount of radioactive gaseous chemicals that are released in the hot cell. It is gentler and more secure compared to the known process and provides access to radiosyntheic processes that may not been acceptable for safety reasons related to release of volatile radioactive gases during evaporation. In addition, the process yields are higher because the radioactive volatiles are labelled intermediate species.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: August 17, 2021
    Assignee: GE HEALTHCARE LIMITED
    Inventors: Xavier Franci, Steve Lignon, Audrey Lange
  • Patent number: 11078254
    Abstract: Provided is a highly sensitive and less expensive lectin-immobilized base material (for example, a lectin plate), such as lectin-immobilized base material having stable qualities and being able to be sufficiently washed after a target sugar chain-containing antigen binds thereto. Further provided is a method for immobilizing lectin to a base material therefor. Particularly provided are: a method whereby a lectin-peptide fusion, in which a peptide capable of adsorbing to a base material surface such as a polystyrene (PS) tag is fused with the N-terminal side or C-terminal side of lectin capable of recognizing a target sugar chain, is immobilized on the peptide side to a base material; and a lectin-immobilized base material produced by this method. By using the lectin-immobilized base material, a target sugar chain-containing antigen can be highly sensitively and evenly measured and, moreover, target sugar chain-containing cells, etc. can be separated (concentrated and harvested).
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: August 3, 2021
    Assignees: National Institute of Advanced Industrial Science and Technology, Nissan Chemical Corporation, National University Corporation Kyoto Institute of Technology
    Inventors: Hiroaki Tateno, Junko Katayama, Kazutaka Matoba, Yoichi Kumada
  • Patent number: 11066446
    Abstract: A cyclic peptide is represented by Formula (I), RN—Xg—[Xi—Xa—Xm—X1—X2—X3—Xn—Xb—Xj]k—Xh—RC??(I) in Formula (I), RN represents an N-terminal group; RC represents a C-terminal group; X1 represents an L-leucine residue, an L-isoleucine residue, an L-methionine residue, an L-lysine residue, or an L-arginine residue; X2 represents an L-valine residue or an L-isoleucine residue; X3 represents an L-tryptophan residue or an L-phenylalanine residue; one of Xa and Xb represents an amino acid residue derived from an amino acid having an azide group on a side chain and the other represents an amino acid residue derived from an amino acid having an alkynyl group on a side chain, and Xg, Xh, Xi, Xj, Xm, and Xn each represent g consecutive X's, h consecutive X's, i consecutive X's, j consecutive X's, m consecutive X's, and n consecutive X's; X represents an amino acid residue.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: July 20, 2021
    Assignee: FUJIFILM Corporation
    Inventor: Koichi Minami
  • Patent number: 10975089
    Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: April 13, 2021
    Assignee: Clarity Pharmaceuticals Ltd
    Inventors: Nicholas Alan Zia, Paul Stephen Donnelly
  • Patent number: 10934332
    Abstract: Aggregated Tau protein is associated with over 20 neurological disorders including Alzheimer's disease. Previous work has shown that Tau's sequence segments VQIINK (SEQ ID NO: 11) and VQIVYK (SEQ ID NO: 9) drive its aggregation, and that inhibitors based on the structure of the VQIVYK (SEQ ID NO: 9) segment partially inhibit Tau aggregation. Here we show that the VQIINK (SEQ ID NO: 11) segment is the more powerful driver of Tau aggregation. Two structures of this segment determined by the cryo EM method MicroED explain its more powerful seeding. Of practical significance, the understanding of the structures has led to the design of structure based peptide inhibitors that effectively inhibit Tau aggregation as well as the ability of exogenous Tau fibrils to seed intracellular Tau in mammalian cells into amyloid.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: March 2, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David S. Eisenberg, Paul M. Seidler, David R. Boyer
  • Patent number: 10927132
    Abstract: A process for the preparation of a radionuclide imaging agent includes providing an imaging agent including a chelated place-holder metal; loading the imaging agent onto an acid stable stationary phase; replacing the chelated place-holder metal of the imaging agent loaded on the stationary phase with a replacement radioactive metal under mild reaction conditions; and eluting the imaging agent including the chelated replacement radioactive metal from the stationary phase to provide a radionuclide imaging agent suitable for positron emission tomography (PET) or single-photon emission computed tomography (SPECT). The imaging agent can include a targeting agent that is directly conjugated to the imaging agent or by means of a linker. The process may also apply to other metals that are non-radioactive but used as diluent metals or other metals that are strongly bound to DOTA.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: February 23, 2021
    Assignee: Rochester Institute of Technology
    Inventors: Hans F. Schmitthenner, Anne M. Sweeney-Jones, Scott Williams
  • Patent number: 10913771
    Abstract: Provided is a novel peptide for preventing or treating inflammatory diseases and a use thereof. According to the novel dimeric or trimeric peptide, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances. Therefore, it is expected that the peptide can be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: February 9, 2021
    Assignee: KINE SCIENCES CO., LTD.
    Inventors: Dae Ho Cho, Kyung Eun Kim, Sun Young Park, Myung Jin Jung, Joo Hyun Lee
  • Patent number: 10907212
    Abstract: Nectin-4 and Nectin-1 in cancer progression/development and as a therapeutic target for cancer.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: February 2, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Amy P. Skubitz, Kristin L. M. Boylan, Petra Buchanan, Rory Manion
  • Patent number: 10898126
    Abstract: The present invention provides a triple fusion imaging device for sentinel lymphadenectomy for laparoscopic surgery including: a composite laparoscope for near infrared ray/gamma ray/visible ray acquisition configured to acquire triple images of a gamma ray from a gamma ray radioactive material injected to a diseased part, a visible ray, and a near infrared ray; an optical fiber configured to transmit the triple images acquired from the composite laparoscope; an optical source configured to generate a white light for acquiring a visible image through the optical fiber and a near infrared ray excitation light for acquiring a near infrared ray image by exciting a near infrared ray emitting fluorescence material at the disease part; an optical-to-electrical conversion module configured to separate individual images of the visible ray, near infrared ray and gamma ray from the triple images delivered through the optical fiber and then respectively convert the individual images to electrical signals; a matching uni
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: January 26, 2021
    Assignees: EULJI UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION, SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCE
    Inventors: Seong Jong Hong, Han Gyu Kang, Gun Chul Hong, Hyung Seok Lee, Kyeong Min Kim, Ho Young Lee, Seung Hoon Lee, Jong Hun Lee
  • Patent number: 10858450
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: December 8, 2020
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Patent number: 10729793
    Abstract: The invention relates to a method of imaging arthritis in a subject, comprising administering to the subject a tracer which comprises a peptide conjugated to a radionuclide, and imaging the subject by 2D nuclear imaging or by 3D detection of single-photon emission events.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: August 4, 2020
    Assignee: GUY'S AND ST. THOMAS' HOSPITAL NHS FOUNDATION TRUST
    Inventor: Toby Garrood
  • Patent number: 10723778
    Abstract: Variant peptides of calcitonin gene-related peptide alpha (?CGRP), calcitonin gene-related peptide beta (?CGRP), and adrenomedullin (AM) are disclosed, wherein the variant peptides have high binding affinity and agonistic or antagonistic activity for at least one receptor complex of CLR:RAMP1, CLR:RAMP2, and CLR:RAMP3. Also disclosed are methods of use of the variant peptides in therapeutic treatments.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: July 28, 2020
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Augen A. Pioszak
  • Patent number: 10718006
    Abstract: An electrochemical method is provided for in-vitro determination of the presence of bacteria producing lactamases, in a sample that may contain such bacteria.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: July 21, 2020
    Assignees: UNIVERSITE DE BOURGOGNE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE DIJON, INSTITUT NATIONAL DE LA RECHERCHE AGRONMIQUE
    Inventors: Murielle Dequaire-Rochelet, Alain Hartmann, Catherine Neuwirth, Benoit Chantemesse
  • Patent number: 10660937
    Abstract: Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of glucagon-like peptide-1 receptor antagonist (GLP1RA) exendin(9-39). Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery or gastrointestinal surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA exendin(9-39).
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: May 26, 2020
    Inventors: Tracey L. McLaughlin, Colleen M. Craig
  • Patent number: 10646593
    Abstract: The present disclosure provides activatable and detectable membrane-interacting peptides that, following activation, can interact with phospholipid bilayers, such as cell membranes. The present disclosure also provides methods of use of such compounds. The compounds of the present disclosure are of the general structure X1a-A-X2-Z-X1b, where A is a membrane-interacting peptide region having a plurality of nonpolar hydrophobic amino acid residues that, following separation from portions Z, is capable of interaction with a phospholipid bilayer; Z is an inhibitory peptide region that can inhibit the activity of portion A; X2 is a cleavable linker that can be cleaved to release cleavage products from the compound; and X1a and X1b are optionally-present chemical handles that facilitate conjugation of various cargo moieties to the compound. Prior to cleavage of the composition at X2, the composition acts as a promolecule that does not associate with cellular membranes to a significant or detectable level.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: May 12, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael Page, Charles S. Craik
  • Patent number: 10639379
    Abstract: The present invention provides a compound that can be used for targeted drug delivery, imaging a patient, or diagnosing a subject for a clinical condition which is believed to be associated with overexpression and/or upregulation of CXCR4. In particular, the present invention provides a high affinity CXCR4 selective binding ligand peptide conjugate (PC) of the Formula: P-(L-A)n (I) or a pharmaceutically acceptable salt thereof, and a method for using and producing the same. The high affinity CXCR4 selective binding ligand peptide conjugate (PC) of the invention is useful in diagnosing, treating or imaging a patient. In compound of Formula (I), n is an integer from 1 to the sum of (the total number of amino acid resides in P and the total number of side-chain functional group in the amino acid residue of P); each A is independently a diagnostic agent, a therapeutic agent, or an imaging agent; L is a linker or absent; and P is a high affinity CXCR4 selective binding peptidyl ligand.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: May 5, 2020
    Assignee: Mainline Biosciences LLC
    Inventors: Junge Zhang, Liang Zeng Yan
  • Patent number: 10596278
    Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: March 24, 2020
    Assignee: ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L.
    Inventors: Francesco de Palo, Lorenza Fugazza, Donato Barbato, Maurizio Mariani, Daniela Chicco, Giovanni Tesoriere, Clementina Brambati
  • Patent number: 10596276
    Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: March 24, 2020
    Assignee: ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L.
    Inventors: Francesco de Palo, Lorenza Fugazza, Donato Barbato, Maurizio Mariani, Daniela Chicco, Giovanni Tesoriere, Clementina Brambati
  • Patent number: 10588963
    Abstract: The invention relates to the fields of immunology and vaccinology. Provided is a method for preparing adjuvanted virosomes, comprising the steps of: (i) providing an aqueous composition of non-adjuvanted virosomes comprising a membrane fusion protein; (ii) dissolving an amphiphilic adjuvant in a pharmaceutically acceptable non-aqueous solvent which can form a homogeneous mixture with water; and (iii) diluting said adjuvant solution in said aqueous virosome composition to induce insertion of adjuvant in the outer leaflet of the virosomal membrane while preserving membrane fusion activity of the virosomes. Also provided are adjuvanted virosomes obtainable by said method, and vaccines comprising the virosomes.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: March 17, 2020
    Assignee: BESTEWIL HOLDING B.V.
    Inventors: Antonius Johannes Henrikus Stegmann, Joan Claudia Maureen Soei-Ken Tjon
  • Patent number: 10548997
    Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: February 4, 2020
    Assignees: Sloan-Kettering Institute for Cancer Research, Cornell University
    Inventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Hooisweng Ow, Andrew Burns, Jason S. Lewis, Steven M. Larson
  • Patent number: 10550194
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: February 4, 2020
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Patent number: 10512691
    Abstract: The present invention relates to nanoparticles. In particular, the present invention provides nanoparticles for clinical (e.g., targeted therapeutic), diagnostic (e.g., imaging), and research applications in the field of cardiology. For example, in some embodiments, the present invention provides a method of treating (e.g., ablating) cardiac tissue, comprising: a) contacting an animal with a nanoparticle comprising a matrix, a toxic (e.g., ablative) agent (e.g., sonosensitizer, chemotherapeutic agent (e.g., doxorubicin or cisplatin), or photosensitizer), and a cardiac targeting moiety; and b) administering an activator of the toxic agent (e.g., light, chemical (e.g., pharmaceutical agent) or ultrasound) to at least a portion of the cardiac tissue (e.g., heart) of the animal to activate the toxic agent.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: December 24, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jerome Kalifa, Raoul Kopelman, Uma Mahesh R. Avula, Gwangseong Kim, Yong-Eun Koo Lee, Hyung Ki Yoon
  • Patent number: 10508137
    Abstract: Disintegrin variants that bind specifically to one or more of ?5?1 and ?v integrins, such as ?v?1, ?v?3, ?v?5, ?v?6 and ?v?8, but with reduced binding activity to ?IIb?3, are described. Also described are uses of the disintegrin variants for the treatment or prevention of a disease associated with an ?v integrin or an ?5?1 integrin.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: December 17, 2019
    Assignee: NATIONAL CHENG KUNG UNIVERISTY
    Inventor: Woei-Jer Chuang
  • Patent number: 10507227
    Abstract: A method for treating an infection comprises administering a peptide in synergistic combination with an antibiotic, wherein the peptide comprises an amino acid sequence with a formula selected from the group consisting of: Bn1-Z;??(a) Bn1-Z-Bn2; and??(b) Z-Bn1??(c) wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of from about 7 to about 24 amino acid residues, said sequence having an average hydrophobicity value of at least 0.3 on the Liu-Deber scale.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: December 17, 2019
    Assignee: The Hospital for Sick Children
    Inventor: Charles M. Deber
  • Patent number: 10464985
    Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue and decreased renal uptake in kidney, evidencing favorable pharmacokinetics of compounds of the present invention. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful for initiating therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: November 5, 2019
    Assignee: STC.UNM
    Inventors: Yubin Miao, Haixun Guo
  • Patent number: 10407475
    Abstract: The present invention relates to a novel protein secretion factor, a vector including a nucleic acid sequence encoding the protein secretion factor, and a transformed cell into which the vector is introduced. The invention also relates to a method of producing a target protein using the transformed cell including the vector.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: September 10, 2019
    Assignee: LG CHEM, LTD.
    Inventors: Seung Hae Kim, Yeon Chul Kim, Saem Jung
  • Patent number: 10407477
    Abstract: Disclosed are knottin peptides containing non-natural amino acids so that they can be formed by chemical conjugation into two or more knottin monomers. The knottin monomers comprise a non-natural amino acid such as an aminooxy residue within the polypeptide sequence. The exemplified dimers were produced by oxime formation between two aldehyde groups present on a polyether linker and an aminooxy functional group that was site-specifically incorporated the knottin. Knottins variants based on EETI (Ecballium elaterium trypsin inhibitor) and AgRP (Agouti-related protein) were engineered to contain integrin-binding loops. These dimers were shown to have increased binding strength to integrins on U87MG tumor cells, achieving significant increases in inhibition of cell adhesion and proliferation. Also disclosed are knottin monomers comprising an aminooxy residue; these may be conjugated to molecules such as doxorubicin.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 10, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jennifer R. Cochran, Jun Woo Kim, Frank V. Cochran
  • Patent number: 10363324
    Abstract: This invention relates to a pharmaceutical composition for parenteral or oral administration containing a radioactive compound which can be used diagnostically or therapeutically. The composition comprises a micro-emulsion constituted by a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous or other pharmacologically acceptable carrier in which nitrous oxide is dissolved, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids, and the radioactive compound.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: July 30, 2019
    Assignees: The South African Nuclear Energy Corporation Limited, North-West University
    Inventors: Anne Frederica Grobler, Jan Rijn Zeevaart
  • Patent number: 10358452
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: July 23, 2019
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 10285930
    Abstract: The present invention relates to the cosmetic and/or nutraceutical use of an extract of the Lythrum salicaria plant and/or of gallic acid and/or one of the gallic acid derivatives, in particular vescalagin and/or castalagin. Provided is a cosmetic care process comprising the application, preferably topically, of the Lythrum salicaria extract according to the invention and/or of gallic acid and/or of one of the gallic acid derivatives, in particular vescalagin and/or castalagin, more preferentially castalagin, or of a cosmetic composition comprising it, for maintaining and/or increasing collagen expression in the skin and/or the mucous membranes, for increasing the firmness of the skin and/or of the mucous membranes and/or maintaining and/or increasing lipolysis in skin adipocytes for inducing a slimming effect onto the skin and/or decreasing, preventing and/or treating the unaesthetic manifestations of cellulite, for example the orange peel appearance of the skin and/or the jodhpur thigh appearance.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 14, 2019
    Assignee: BASF Beauty Care Solutions France SAS
    Inventors: Lysianne Cittadini, Louis Danoux, Nathalie Godard
  • Patent number: 10258701
    Abstract: Disclosed is a compound of formula (I): wherein L, R1-R5, A, B, M, and n are as defined in the specification, as well as a method of preparing the compound. Also disclosed are a method of blood-pool imaging in a mammal and a method of imaging a lymph node in a mammal, comprising use of the compound.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: April 16, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Xiaoyuan Chen, Lixin Lang, Gang Niu
  • Patent number: 10232058
    Abstract: Urea-based photosensitizers, which target prostate-specific membrane antigen (PSMA) for imaging and targeted therapy of PSMA-expressing tumors and cancers are disclosed.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: March 19, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Ronnie Mease, Ying Chen
  • Patent number: 10220076
    Abstract: Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: March 5, 2019
    Assignee: InCube Labs, LLC
    Inventors: Mercedes Morales, Mir Imran, Radhika Korupolu, Mir Hashim
  • Patent number: 10220101
    Abstract: The present invention relates to a composition and a combination comprising at least one first drug and at least one protein-binding prodrug, wherein the proteinbinding prodrug comprises a protein-binding group, a second drug, and a linker that can be cleaved hydrolytically, enzymatically, or in a pH-dependent manner in the body, as well as to a kit and a pharmaceutical composition comprising said composition or combination.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: March 5, 2019
    Assignee: Vergell Medical S.A.
    Inventor: Felix Kratz